Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PPME1 | Q9Y570 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4169998 | 1.00 | LMNA (0.39) | LMNARORCIDO1MAOBMAPT | |
| SCHEMBL4169994 | 1.00 | LMNA (0.39) | LMNARORCIDO1MAOBMAPT | |
| SCHEMBL4179906 | 0.88 | LMNA (0.51) | LMNAMAPTPPME1EGFRERBB2 | |
| SCHEMBL4179908 | 0.88 | LMNA (0.51) | LMNAMAPTPPME1EGFRERBB2 | |
| SCHEMBL4179898 | 0.88 | LMNA (0.51) | LMNAMAPTPPME1EGFRERBB2 | |
| SCHEMBL4185371 | 0.85 | SIRT2 (0.43) | LMNAMAOBMAPTTP53EGFR | |
| SCHEMBL4185378 | 0.85 | SIRT2 (0.43) | LMNAMAOBMAPTTP53EGFR | |
| SCHEMBL4185381 | 0.85 | SIRT2 (0.43) | LMNAMAOBMAPTTP53EGFR | |
| SCHEMBL4182685 | 0.79 | EGFR (0.36) | LMNAMAPTEGFRERBB2NLRP3 | |
| SCHEMBL4182678 | 0.79 | EGFR (0.36) | LMNAMAPTEGFRERBB2NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-07-30 | — | — | US | claimed |
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-07-30 | — | — | US | disclosed |
| EP-2046322-A2 | ARYL VINYL SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008016682-A2 | ARYL VINYL SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | ARSA, STS, SULT2A1 | LMNA 4621/4885RORC 742/4885IDO1 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.